Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hanover Labs' LIPO/trim

This article was originally published in The Tan Sheet

Executive Summary

FDA sends Livingston, N.J. manufacturer an Aug. 9 warning letter regarding LIPO/trim tablets, which contain chromium picolinate and a blend of Micro-C-Cellulose, gelatin, Uva Ursa and oat fiber. The agency said that Hanover is marketing the product as a "misbranded" weight control drug through product labeling and advertising that calls LIPO/trim "the most effective, natural appetite control tablets available today" and "an all natural diet pill." FDA said it is "unaware of any substantial scientific evidence" that demonstrates that LIPO/trim tablets "are generally recognized as safe and effective." In May, Hanover agreed to "reassess and modify [its] advertising" following a review by the National Advertising Division of the Council of Better Business Bureaus ("The Tan Sheet" May 10, p. 13). . . .

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS081851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel